Positive Phase 1 Study Results for AX-0810 Indicate Significant NTCP Modulation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 25 2026
0mins
Source: Newsfilter
- Dose-Dependent Target Engagement: AX-0810 demonstrated up to an 8-fold increase in total bile acids in serum at 3 mg/kg and 6 mg/kg doses, exceeding the company's 2-fold threshold for meaningful NTCP modulation, indicating potential new treatment avenues for cholestatic liver diseases like biliary atresia.
- Favorable Safety and Tolerability: To date, AX-0810 has shown no serious adverse events or pruritus in the clinical trial, reflecting a favorable safety profile, while pharmacokinetic data indicate a sustained target engagement with an 8-week half-life, enhancing its clinical applicability.
- Biomarker Findings Support Further Research: The biomarker results from AX-0810 support the advancement of the next-generation candidate AX-0811, which has shown significant cholestasis reduction in animal models, with a Clinical Trial Application expected in mid-2026, broadening the prospects for NTCP-targeted therapies.
- Future Development Plans: ProQR intends to conduct an investigator-initiated trial in pediatric biliary atresia in China, with initial clinical data anticipated in the first half of 2027, marking a significant step towards addressing unmet medical needs with AX-0810 and AX-0811 in Phase 2 development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRQR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRQR
Wall Street analysts forecast PRQR stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.660
Low
5.00
Averages
8.67
High
12.00
Current: 1.660
Low
5.00
Averages
8.67
High
12.00
About PRQR
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ProQR Announces Underwritten Direct Offering, Shares Drop 20%
- Offering Overview: ProQR Therapeutics announced the completion of an underwritten registered direct offering of 27,624,810 ordinary shares at $1.1 per share, with gross proceeds estimated at $50 million, indicating an urgent need for financing amid market pressures.
- Strategic Partnership Agreement: Concurrently, the company entered into a purchase agreement with strategic partner Eli Lilly for 5,100,780 ordinary shares, expected to generate $9.2 million, aimed at strengthening collaboration and funding future research initiatives.
- Use of Proceeds: ProQR plans to allocate the proceeds from this offering to fund research and clinical development of current or additional pipeline candidates, as well as for working capital, capital expenditures, and other general corporate purposes, highlighting the company's commitment to R&D.
- Market Reaction Analysis: Despite a significant drop of over 20% in share price on Thursday, closing at $1.44, shares showed a slight recovery in pre-market trading to $1.57, reflecting a complex market reaction and cautious investor sentiment regarding the company's future prospects.
See More
ProQR Therapeutics Prices $50M Direct Offering of 27.6M Shares
- Offering Size: ProQR Therapeutics has priced a registered direct offering of 27.6 million ordinary shares at $1.81 per share, aiming to raise approximately $50 million in gross proceeds before expenses to support its research and clinical development initiatives.
- Strategic Partnership: Existing shareholder Eli Lilly has agreed to purchase 5.1 million ordinary shares at the same price, valued at about $9.2 million, which will help Lilly maintain its pro rata beneficial ownership and further solidify their strategic partnership.
- Use of Proceeds: ProQR plans to utilize the proceeds from both transactions, along with its existing cash, to fund research, clinical development, working capital, capital expenditures, and other general corporate purposes, ensuring the company's ongoing operations and growth.
- Market Reaction: Following the financing announcement, ProQR shares rose by 1.48% in premarket trading, indicating a positive market response to the company's financing plans, which may enhance investor confidence.
See More
ProQR Therapeutics Reports Positive Phase 1 Data for AX-0810
- Clinical Trial Results: ProQR Therapeutics announced that its Phase 1 trial for AX-0810, involving 22 healthy volunteers, demonstrated a favorable safety and tolerability profile, with no serious adverse events reported, indicating the therapy's potential in liver disease treatment.
- Mechanism of Action: AX-0810 modulates NTCP, a bile acid transporter, resulting in up to an eight-fold increase in serum bile acids, significantly exceeding the predefined two-fold threshold, which confirms its effectiveness as a novel therapeutic target.
- Market Potential: The data supports ProQR's advancement of its NTCP franchise, including AX-0810 and its sister therapy, particularly targeting biliary atresia, a cholestatic liver disease, suggesting promising future market opportunities.
- Strategic Partnerships: ProQR has formed a partnership with Ginkgo as part of its AI strategy, aimed at accelerating drug development and market entry, thereby enhancing its competitive position in the biotech sector.
See More
ProQR Reports Positive Data from AX-0810 Phase 1 Study
- Clinical Trial Progress: ProQR Therapeutics N.V. has enrolled 33 healthy volunteers in its Phase 1 study of AX-0810, with 24 receiving the treatment, demonstrating good safety and tolerability, indicating potential for future research.
- Biomarker Results: In the 3 mg/kg and 6 mg/kg cohorts, AX-0810 resulted in up to an 8-fold increase in total bile acids in serum, exceeding the company's predefined target of 2-fold, showcasing effective NTCP modulation and potential new avenues for treating liver-related diseases.
- Increased Urinary Excretion: The administration of AX-0810 led to statistically significant increases in urinary excretion of conjugated bile acids, suggesting that the drug may lower toxic bile acid concentrations in the body through NTCP modulation, thereby improving liver health.
- Future Development Plans: ProQR intends to submit a Clinical Trial Application for AX-0811 in mid-2026 and anticipates initial human clinical data by the end of 2026, reflecting the company's ongoing investment and commitment to research in the NTCP space.
See More
Positive Phase 1 Study Results for AX-0810 Indicate Significant NTCP Modulation
- Dose-Dependent Target Engagement: AX-0810 demonstrated up to an 8-fold increase in total bile acids in serum at 3 mg/kg and 6 mg/kg doses, exceeding the company's 2-fold threshold for meaningful NTCP modulation, indicating potential new treatment avenues for cholestatic liver diseases like biliary atresia.
- Favorable Safety and Tolerability: To date, AX-0810 has shown no serious adverse events or pruritus in the clinical trial, reflecting a favorable safety profile, while pharmacokinetic data indicate a sustained target engagement with an 8-week half-life, enhancing its clinical applicability.
- Biomarker Findings Support Further Research: The biomarker results from AX-0810 support the advancement of the next-generation candidate AX-0811, which has shown significant cholestasis reduction in animal models, with a Clinical Trial Application expected in mid-2026, broadening the prospects for NTCP-targeted therapies.
- Future Development Plans: ProQR intends to conduct an investigator-initiated trial in pediatric biliary atresia in China, with initial clinical data anticipated in the first half of 2027, marking a significant step towards addressing unmet medical needs with AX-0810 and AX-0811 in Phase 2 development.
See More
ProQR Therapeutics Completes $50 Million Financing
- Financing Size: ProQR Therapeutics announced the pricing of 27,624,310 ordinary shares at $1.81 each, expecting gross proceeds of approximately $50 million, indicating strong market demand for its RNA therapies.
- Strategic Partnership: ProQR has entered into a share purchase agreement with Eli Lilly, allowing Lilly to purchase 5,100,780 shares at the same offering price, thereby maintaining its ownership stake and reinforcing their strategic partnership.
- Use of Proceeds: The proceeds from this offering will primarily fund research and clinical development of existing and new pipeline candidates, reflecting the company's proactive investment strategy for future product development.
- Underwriter Lineup: BofA Securities, Evercore ISI, and Cantor are acting as joint lead bookrunning managers for the offering, demonstrating market confidence in ProQR, with the financing expected to close on June 26, 2026.
See More
ProQR Announces Underwritten Direct Offering, Shares Drop 20%
- Offering Overview: ProQR Therapeutics announced the completion of an underwritten registered direct offering of 27,624,810 ordinary shares at $1.1 per share, with gross proceeds estimated at $50 million, indicating an urgent need for financing amid market pressures.
- Strategic Partnership Agreement: Concurrently, the company entered into a purchase agreement with strategic partner Eli Lilly for 5,100,780 ordinary shares, expected to generate $9.2 million, aimed at strengthening collaboration and funding future research initiatives.
- Use of Proceeds: ProQR plans to allocate the proceeds from this offering to fund research and clinical development of current or additional pipeline candidates, as well as for working capital, capital expenditures, and other general corporate purposes, highlighting the company's commitment to R&D.
- Market Reaction Analysis: Despite a significant drop of over 20% in share price on Thursday, closing at $1.44, shares showed a slight recovery in pre-market trading to $1.57, reflecting a complex market reaction and cautious investor sentiment regarding the company's future prospects.
See More
ProQR Therapeutics Prices $50M Direct Offering of 27.6M Shares
- Offering Size: ProQR Therapeutics has priced a registered direct offering of 27.6 million ordinary shares at $1.81 per share, aiming to raise approximately $50 million in gross proceeds before expenses to support its research and clinical development initiatives.
- Strategic Partnership: Existing shareholder Eli Lilly has agreed to purchase 5.1 million ordinary shares at the same price, valued at about $9.2 million, which will help Lilly maintain its pro rata beneficial ownership and further solidify their strategic partnership.
- Use of Proceeds: ProQR plans to utilize the proceeds from both transactions, along with its existing cash, to fund research, clinical development, working capital, capital expenditures, and other general corporate purposes, ensuring the company's ongoing operations and growth.
- Market Reaction: Following the financing announcement, ProQR shares rose by 1.48% in premarket trading, indicating a positive market response to the company's financing plans, which may enhance investor confidence.
See More
ProQR Therapeutics Reports Positive Phase 1 Data for AX-0810
- Clinical Trial Results: ProQR Therapeutics announced that its Phase 1 trial for AX-0810, involving 22 healthy volunteers, demonstrated a favorable safety and tolerability profile, with no serious adverse events reported, indicating the therapy's potential in liver disease treatment.
- Mechanism of Action: AX-0810 modulates NTCP, a bile acid transporter, resulting in up to an eight-fold increase in serum bile acids, significantly exceeding the predefined two-fold threshold, which confirms its effectiveness as a novel therapeutic target.
- Market Potential: The data supports ProQR's advancement of its NTCP franchise, including AX-0810 and its sister therapy, particularly targeting biliary atresia, a cholestatic liver disease, suggesting promising future market opportunities.
- Strategic Partnerships: ProQR has formed a partnership with Ginkgo as part of its AI strategy, aimed at accelerating drug development and market entry, thereby enhancing its competitive position in the biotech sector.
See More
ProQR Reports Positive Data from AX-0810 Phase 1 Study
- Clinical Trial Progress: ProQR Therapeutics N.V. has enrolled 33 healthy volunteers in its Phase 1 study of AX-0810, with 24 receiving the treatment, demonstrating good safety and tolerability, indicating potential for future research.
- Biomarker Results: In the 3 mg/kg and 6 mg/kg cohorts, AX-0810 resulted in up to an 8-fold increase in total bile acids in serum, exceeding the company's predefined target of 2-fold, showcasing effective NTCP modulation and potential new avenues for treating liver-related diseases.
- Increased Urinary Excretion: The administration of AX-0810 led to statistically significant increases in urinary excretion of conjugated bile acids, suggesting that the drug may lower toxic bile acid concentrations in the body through NTCP modulation, thereby improving liver health.
- Future Development Plans: ProQR intends to submit a Clinical Trial Application for AX-0811 in mid-2026 and anticipates initial human clinical data by the end of 2026, reflecting the company's ongoing investment and commitment to research in the NTCP space.
See More
Positive Phase 1 Study Results for AX-0810 Indicate Significant NTCP Modulation
- Dose-Dependent Target Engagement: AX-0810 demonstrated up to an 8-fold increase in total bile acids in serum at 3 mg/kg and 6 mg/kg doses, exceeding the company's 2-fold threshold for meaningful NTCP modulation, indicating potential new treatment avenues for cholestatic liver diseases like biliary atresia.
- Favorable Safety and Tolerability: To date, AX-0810 has shown no serious adverse events or pruritus in the clinical trial, reflecting a favorable safety profile, while pharmacokinetic data indicate a sustained target engagement with an 8-week half-life, enhancing its clinical applicability.
- Biomarker Findings Support Further Research: The biomarker results from AX-0810 support the advancement of the next-generation candidate AX-0811, which has shown significant cholestasis reduction in animal models, with a Clinical Trial Application expected in mid-2026, broadening the prospects for NTCP-targeted therapies.
- Future Development Plans: ProQR intends to conduct an investigator-initiated trial in pediatric biliary atresia in China, with initial clinical data anticipated in the first half of 2027, marking a significant step towards addressing unmet medical needs with AX-0810 and AX-0811 in Phase 2 development.
See More
ProQR Therapeutics Completes $50 Million Financing
- Financing Size: ProQR Therapeutics announced the pricing of 27,624,310 ordinary shares at $1.81 each, expecting gross proceeds of approximately $50 million, indicating strong market demand for its RNA therapies.
- Strategic Partnership: ProQR has entered into a share purchase agreement with Eli Lilly, allowing Lilly to purchase 5,100,780 shares at the same offering price, thereby maintaining its ownership stake and reinforcing their strategic partnership.
- Use of Proceeds: The proceeds from this offering will primarily fund research and clinical development of existing and new pipeline candidates, reflecting the company's proactive investment strategy for future product development.
- Underwriter Lineup: BofA Securities, Evercore ISI, and Cantor are acting as joint lead bookrunning managers for the offering, demonstrating market confidence in ProQR, with the financing expected to close on June 26, 2026.
See More
